Literature DB >> 18766364

Exacerbation of central serous chorioretinopathy following intravitreal triamcinolone injection.

M Selim Kocabora1, Sahan Durmaz, Nilay Kandemir.   

Abstract

BACKGROUND: This report describes a case of central serous chorioretinopathy following intravitreal triamcinolone acetonide injection.
METHODS: A 42-year-old man presented with a 4-month history of decreased visual acuity (0.4) in his left eye. The left eye demonstrated macular edema due to branch retinal vein occlusion. Triamcinolone acetonide 4 mg/ 0.1 mL was injected intravitreally to treat the macular edema.
RESULTS: Pigmentary retinal discoloration, retinal pigment epithelium leakage and a slight neurosensorial detachment with cystoid macular edema at the temporal macula were present prior to intravitreal triamcinolone injection. Three weeks after injection, visual acuity had decreased to 0.2 and metamorphopsies appeared in the left eye. A sharply demarcated serous macular elevation and a progressively increasing hyperfluorescence of the pre-existing leakage point led to the diagnosis of "exacerbation of the pre-existing asymptomatic central serous chorioretinopathy" following intravitreal triamcinolone injection. Macular elevation spontaneously resolved by the 4th month post-injection. At the 6th month, the patient experienced recurrence of a small serous detachment at the temporal macula.
CONCLUSION: Central serous chorioretinopathy exacerbation may arise as a complication of intravitreal triamcinolone acetonide injection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18766364     DOI: 10.1007/s00417-008-0932-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  10 in total

1.  Central serous chorioretinopathy may be a manifestation of the primary antiphospholipid syndrome.

Authors:  M T Costen; J A Olson
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

Review 2.  Central serous chorioretinopathy and glucocorticoids.

Authors:  Evrydiki A Bouzas; Panagiotis Karadimas; Constantin J Pournaras
Journal:  Surv Ophthalmol       Date:  2002 Sep-Oct       Impact factor: 6.048

Review 3.  Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.

Authors:  Jost B Jonas
Journal:  Acta Ophthalmol Scand       Date:  2005-12

4.  Intravitreal triamcinolone acetonide and central serous chorioretinopathy.

Authors:  J B Jonas; B A Kamppeter
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

5.  Central serous chorioretinopathy following vitrectomy with intravitreal triamcinolone acetonide for diabetic macular oedema.

Authors:  Mitsuhiro Imasawa; Tomohiro Ohshiro; Teruhiko Gotoh; Masahito Imai; Hiroyuki Iijima
Journal:  Acta Ophthalmol Scand       Date:  2005-02

6.  Resolution of serous macular detachment after intravitreal triamcinolone acetonide treatment of patients with branch retinal vein occlusion.

Authors:  Murat Karacorlu; Hakan Ozdemir; Serra Arf Karacorlu
Journal:  Retina       Date:  2005 Oct-Nov       Impact factor: 4.256

7.  Serous macular detachment in branch retinal vein occlusion.

Authors:  Yumiko Yamaguchi; Tomohiro Otani; Shoji Kishi
Journal:  Retina       Date:  2006 Nov-Dec       Impact factor: 4.256

8.  Ocular symptoms in association with antiphospholipid antibodies.

Authors:  B Leo-Kottler; R Klein; P A Berg; E Zrenner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1998-09       Impact factor: 3.117

Review 9.  Central serous chorioretinopathy.

Authors:  Maria Wang; Inger Christine Munch; Pascal W Hasler; Christian Prünte; Michael Larsen
Journal:  Acta Ophthalmol       Date:  2007-07-28       Impact factor: 3.761

10.  Glucocorticoid use represents a risk factor for central serous chorioretinopathy: a prospective, case-control study.

Authors:  Panagiotis Karadimas; Evrydiki A Bouzas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09       Impact factor: 3.117

  10 in total
  9 in total

1.  Development of bullous retinal detachment during systemic corticosteroid treatment.

Authors:  Xinxiao Gao; Xiaoxin Li
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-12-03       Impact factor: 3.117

2.  Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).

Authors:  Baruch D Kuppermann; Leandro Cabral Zacharias; M Cristina Kenney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

3.  Corticosteroid-associated atypical central serous chorioretinopathy in a patient with multiple sclerosis.

Authors:  Mahmut Kaya; Derya Kaya; Egemen Idiman
Journal:  Int J Ophthalmol       Date:  2017-05-18       Impact factor: 1.779

Review 4.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

5.  A novel mutation of sgk-1 gene in central serous chorioretinopathy.

Authors:  Mahmut Akyol; Muhammet Kazım Erol; Ozdemir Ozdemir; Deniz Turgut Coban; Ahmet Burak Bilgin; Esin Sogutlu Sari; Elif Betul Turkoglu
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

6.  Diagnostic and Therapeutic Challenges in a Patient with Radiation Retinopathy Complicated by Corticosteroid-Induced Central Serous Chorioretinopathy.

Authors:  Michał Chrząszcz; Natalia Mackiewicz; Weronika Pociej-Marciak; Bożena Romanowska-Dixon; Agnieszka Kubicka-Trząska; Maciej Gawęcki; Izabella Karska-Basta
Journal:  Medicina (Kaunas)       Date:  2022-06-28       Impact factor: 2.948

7.  Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy.

Authors:  Carl Schubert; Anders Pryds; Shemin Zeng; Yajing Xie; K Bailey Freund; Richard F Spaide; John C Merriam; Irene Barbazetto; Jason S Slakter; Stanley Chang; Inger C Munch; Arlene V Drack; Jasmine Hernandez; Suzanne Yzer; Joanna E Merriam; Allan Linneberg; Michael Larsen; Lawrence A Yannuzzi; Robert F Mullins; Rando Allikmets
Journal:  Hum Mutat       Date:  2014-07       Impact factor: 4.700

8.  Central Serous Chorioretinopathy Misdiagnosed as Posterior Uveitis and the Vicious Circle of Corticosteroid Therapy.

Authors:  Marina Papadia; Bruno Jeannin; Carl P Herbort
Journal:  J Ophthalmic Vis Res       Date:  2015 Jul-Sep

Review 9.  Local delivery of corticosteroids in clinical ophthalmology: A review.

Authors:  Adrian T Fung; Tuan Tran; Lyndell L Lim; Chameen Samarawickrama; Jennifer Arnold; Mark Gillies; Caroline Catt; Logan Mitchell; Andrew Symons; Robert Buttery; Lisa Cottee; Krishna Tumuluri; Paul Beaumont
Journal:  Clin Exp Ophthalmol       Date:  2020-01-22       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.